Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Tuesday, June 30

IPSTE SESINSTac B224-237

22349 Incidence and predictors of virologic failure of antiretroviral triple drug
therapy in a community-based cohort
Stefan Zimmerli*; Stefan Zimmerli; D. Paris; B. Ledergerber, Switzerland
22350 Ritonavir-containing dual protease inhibitor regimens may have
synergistic antiviral effects in patients-based on in vitro model
Ann Hsu*; R. Granneman; A. Molla; S. Vasavanonda; A. Japour; D. Kempf;
E. Sun, USA
22351 Risk factors for virologic failure in a cohort of HIV patients receiving
highly active antiretroviral therapy (HAART)
Zelalem Temesgen*; Elie Berbari; J.H. Henely; L.L. Estes; A.J. Wright, USA
22352 Co-administration of indinavir and nelfinavir: Pharmacokinetics,
tolerability, anti-viral activity, and preliminary viral resistance
Alfred Saah*; Sharon Riddler; D. V. Havlir; K. Squires; R. Anderson; B. Kerr;
K. Yeh; P. Deutsch, USA
22353 Long-term effectiveness of HAART in a large clinical group and the role
of viral resistance in treatment failure
William M. Reitner*; PJ. Cimoch; D.S. Berger; D.M. See; D.E. Vorce;
P. Darmanin; B. Baker, USA
22354 Combination therapy with protease-inhibitor during six to twenty one
months in HIV-infected patients followed by a single physician
M. Kirstetter*;A. Daguenel-Nguyen; G. Kreplak;J.B. Guiard-Schmid;
J. Frottier, France
22355 Patterns of antiretroviral therapy (ART) use from 1988-1998 in a cohort
of 120 HIV+ patients
Michael S. Saag; Stephanie CallI* A. Westfall; S.V. Pham; A. Chatwood;
G. Cloud; J. Raper, USA
22356 Ritonavir,saquinavir,and nevirapine as a salvage regimen forindinavir or
ritonavir resistance
Charles Farthing*; T. Mess; C. Ried; S. Radhakrishna; M. Wallace, USA
22357 Efficacy of the combination stavudine (d4T), didanosine (ddl) and
nevirapine (NVP) as initial antiretroviral therapy and following
treatment with HIV-1 protease inhibitors
Catherine Pell*;M.A. Slade; B. Donovan; NJ. Bodsworth, Australia
22358 Switch in HIV phenotype and identification of reservoir of HIV-1 in CD4
cells in infants and children receiving HAART
YvonneJ. Bryson*; Ozlem Equils; P. Krogstad; L.S. Wei; K. Neilsen;
M. Tapia, USA
22359 Are three drugs enough? Baseline plasma viral load as a predictor of
virologic response to triple therapy
Robert Hogg*;Julio S.G. Montaner; B. Yip; N. Janhke; C. Sherlock;
M.T. Schechter; M. V. O'Shaughnessy, Canada
22360 Influence of antiretroviral combinations on disease progression and
survival in HIV-infected patients, Aquitaine (France), 1988-97
Frantz Thiessard*; L. Dequae; R. Thiebaut; C. Marimoutou; F. Dabis;
R. Salomon; Gecsa, France
22361 Indinavir can be taken with regular meals when administered with
ritonavir
Ann Hsu*; R. Granneman; M. Heath-Chiozzi; C. Wong; L. Manning;
R. Brooks; E. Sun, USA
22362 Combination therapy with nelfinavir, stavudine and lamivudine
(HAART) in HIV-1 infected children: Kinetics of immune reconstitution

Henriette J. Scherpbier*; M.T L. Roos; N.G. Pakker; F De Wolf; S. Jurriaans;
F Miedema; J.M.A. Lange, The Netherlands

22363 Predictors of Success of Antiretroviral Therapy (ART) in a Prospective
Clinic Cohort
MichaelS. Saag*; G.C. Cloud;J. Raper; J.M. Tolson; S. McKinnon;A. Gum;
S. Call, USA
22364 Effect of antiretroviral therapy on viral load and CD4 count in HIVinfected children <36 months of age
Savita Pahwa*; Saroj Bakshi; S. Patrick; M. Morales, USA
22365 The effect of highly active antiretroviral therapy (HAART) and predictors
of undetectable plasma viral loads in 250 HIV(+) women in care
Timothty Flanigan*; N. Merriman; B.P. Dickinson; T. Fiore; K. Tashima;
J. Mitty; C.CJ. Carpenter, USA
22366 Patterns of antiretroviral use in a symptomatic and asymptomatic HIVinfected population in a community-based organisation (CBO) in New
York City
Condrad T. Fischer, Dr.*; Ruby M. Brand-Wachtel, C-ANP; A.J.L. Laurie;
K.A. Atkins; C.T. Fischer, USA
22367 Increasing survival time after AIDS in Italy:The role of new combination
antiretroviral therapies
Giovanni Rezza*; P. Pezzotti; S. Boros; P.A. Napoli; S. Acciai; V. Lazzeri,
Italy
22368 The impact of viral load (VL) nadir on the change of antiretroviral
therapy (ART) and clinical outcome. A prospective multicenter
evaluation (German AIDS Study Group GASG Protocol 022)
Andreas Mihlhifer*; 0. Loch; H.J. Stellbrink; R. Baumgarten;J.R. Bogner;
M. Dietrich; F.D. Goebel, Germany
22369 HAART and Prophylaxis Result in Further Cost Savings by Decreasing
Utilization of Diagnostic Lab
Daniel Klein*;M.H. Katz; L. Hurley; A.M. Vannier, USA
22370 Recent patterns ofantiretroviral prescriptions among HIV-infected
patients in care in the United States
MarkS. Dworkin*; P.C.T. Wan; J.L. Jones, USA
22371 A phase II randomized open label study ofadefovir dipivoxil (PreveonT,
ADV) in combinations with indinavir (IDV),zidovudine (ZDV),
lamivudine (3TC),and stavudine (D4T) in therapy naive HIV-infected
patients
Dean Winslow*;A. Myers; G. Blick; D. Shepp; G. Simon; D. Coakley; J. Lee,
USA
22372 Novel double protease combinations-combining indinavir (IDV) with
ritonavir (RTV): Results from first study
Cassy Workman*; R. Musson; W. Dyer;J. Sullivan, Australia
22373 The impact of highly active antiretroviral therapy on HIV associated
hospital admissions and deaths
Pere Domingo*; J.M. Guardiola; J. Ris, Spain
22374 Decline in mortality rates and opportunistic disease with combination
antiretroviral therapy
Richard Moore*; J.C. Keruly;J. Gallant; R.E. Chaisson, USA
22375 Failure of double protease inhibitor therapy as a salvage therapy for HIVinfected patients resistant to conventional triple therapy
Jiirgen Rockstroh; Markus Altfeld*; B. Kupfer; R. Kaiser; G. Fdtkenheuer;
B. Salberger; U. Spengler, Germany
22376 Virologic efficacy of 3TC + D4T vs. 3TC + D4T + SQV in HIV-1 infected

patients previously treated with ZDV + ddC
Lidia Ruiz*; S. Marfil; T Puig; C. Tural; J. Romeu; G. Sirera; B. Clotet, Spain

92

12th World AIDS Conference Geneva